What is NPCE's current stock price?

NPCE (NeuroPace, Inc.) is currently trading at $16.92 with a market cap of $576.9M.

What sector is NeuroPace, Inc. in?

NeuroPace, Inc. (NPCE) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is NPCE a good stock to buy?

Analysts have a Buy consensus on NPCE with a price target of $21.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NPCE NeuroPace, Inc.

Healthcare

$16.92+3.93%ClosedMarket Cap: $576.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

39.47

P/S

5.80

EV/EBITDA

-42.51

DCF Value

$-32.25

FCF Yield

-1.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

78.3%

Operating Margin

-16.8%

Net Margin

-21.7%

ROE

-120.7%

ROA

-21.8%

ROIC

-19.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$22.1M	$-6.7M	$—
Q4 null	$26.6M	$-2.7M	$—
FY null	$100.0M	$-21.5M	$—
Q3 null	$27.4M	$-3.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$21.00

Target (Median)

$21.00

Target Range

$20.00 - $22.00

1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-15

HC Wainwright & Co.Buy

2026-01-27

UBSBuy

2025-12-16

JP MorganOverweight

2025-12-10

JP MorganOverweight

2025-11-05

Trading Activity

Insider Trades

View All

Williams Patrick F.officer: Chief Financial Officer

SellTue May 19

Williams Patrick F.officer: Chief Financial Officer

SellTue May 19

Morrell Marthaofficer: CHIEF MEDICAL OFFICER

SellTue May 19

Morrell Marthaofficer: CHIEF MEDICAL OFFICER

SellTue May 19

Becker Joeldirector, officer: CHIEF EXECUTIVE OFFICER

SellTue May 19

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.93

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Peers